Ingevity [NGVT] vs Innospec [IOSP] Detailed Stock Comparison
Ingevity
NYSE
Loading...
Innospec
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Ingevity wins in 9 metrics, Innospec wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Ingevity | Innospec | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.96 | 102.32 | Ingevity |
| Price-to-Book Ratio | 15.05 | 1.53 | Innospec |
| Debt-to-Equity Ratio | 1,102.15 | 3.79 | Innospec |
| PEG Ratio | 12.29 | 12.75 | Ingevity |
| EV/EBITDA | 7.66 | 28.64 | Ingevity |
| Profit Margin (TTM) | -16.35% | 1.08% | Innospec |
| Operating Margin (TTM) | 23.53% | 7.96% | Ingevity |
| EBITDA Margin (TTM) | 23.53% | 7.96% | Ingevity |
| Return on Equity | -106.83% | 1.55% | Innospec |
| Return on Assets (TTM) | 8.86% | 0.65% | Ingevity |
| Free Cash Flow (TTM) | $51.00M | $122.20M | Innospec |
| Dividend Yield | N/A | 1.97% | N/A |
| 1-Year Return | 43.98% | -23.47% | Ingevity |
| Price-to-Sales Ratio (TTM) | 1.37 | 1.11 | Innospec |
| Enterprise Value | $3.04B | $1.77B | Ingevity |
| EV/Revenue Ratio | 2.29 | 0.99 | Innospec |
| Gross Profit Margin (TTM) | 37.77% | 28.02% | Ingevity |
| Revenue per Share (TTM) | $36 | $72 | Innospec |
| Earnings per Share (Diluted) | $-5.95 | $0.78 | Innospec |
| Beta (Stock Volatility) | 1.37 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Ingevity vs Innospec Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ingevity | 1.50% | 26.91% | 9.57% | 27.25% | 15.58% | 29.67% |
| Innospec | 2.04% | 3.68% | -8.27% | -12.81% | -26.62% | -24.34% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ingevity | 43.98% | -31.74% | -15.58% | 93.47% | 93.47% | 93.47% |
| Innospec | -23.47% | -18.11% | 3.64% | 75.82% | 598.46% | 905.43% |
Performance & Financial Health Analysis: Ingevity vs Innospec
| Metric | NGVT | IOSP |
|---|---|---|
| Market Information | ||
| Market Cap | $1.82B | $1.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 338,467 | 234,810 |
| 90 Day Avg. Volume | 253,409 | 227,103 |
| Last Close | $51.27 | $81.44 |
| 52 Week Range | $28.49 - $52.05 | $74.10 - $128.35 |
| % from 52W High | -1.50% | -36.55% |
| All-Time High | $120.41 (Feb 18, 2019) | $133.71 (May 06, 2024) |
| % from All-Time High | -57.42% | -39.09% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.07% | 0.01% |
| Quarterly Earnings Growth | -0.07% | -0.25% |
| Financial Health | ||
| Profit Margin (TTM) | -0.16% | 0.01% |
| Operating Margin (TTM) | 0.24% | 0.08% |
| Return on Equity (TTM) | -1.07% | 0.02% |
| Debt to Equity (MRQ) | 1,102.15 | 3.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.31 | $52.19 |
| Cash per Share (MRQ) | $2.11 | $10.69 |
| Operating Cash Flow (TTM) | $215.40M | $136.80M |
| Levered Free Cash Flow (TTM) | $357.79M | $-56,962,500 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.97% |
| Last 12-Month Dividend | N/A | $1.63 |
Valuation & Enterprise Metrics Analysis: Ingevity vs Innospec
| Metric | NGVT | IOSP |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.96 | 102.32 |
| Forward P/E | 12.29 | 12.75 |
| PEG Ratio | 12.29 | 12.75 |
| Price to Sales (TTM) | 1.37 | 1.11 |
| Price to Book (MRQ) | 15.05 | 1.53 |
| Market Capitalization | ||
| Market Capitalization | $1.82B | $1.99B |
| Enterprise Value | $3.04B | $1.77B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.29 | 0.99 |
| Enterprise to EBITDA | 7.66 | 28.64 |
| Risk & Other Metrics | ||
| Beta | 1.37 | N/A |
| Book Value per Share (MRQ) | $3.31 | $52.19 |
Financial Statements Comparison: Ingevity vs Innospec
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NGVT | IOSP |
|---|---|---|
| Revenue/Sales | $284.00M | $440.80M |
| Cost of Goods Sold | $170.60M | $315.70M |
| Gross Profit | $113.40M | $125.10M |
| Research & Development | $7.70M | $12.70M |
| Operating Income (EBIT) | $62.60M | $43.00M |
| EBITDA | $83.20M | $54.10M |
| Pre-Tax Income | $26.80M | $44.40M |
| Income Tax | $6.30M | $11.60M |
| Net Income (Profit) | $20.50M | $32.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NGVT | IOSP |
|---|---|---|
| Cash & Equivalents | $71.50M | $299.80M |
| Total Current Assets | $530.00M | $977.10M |
| Total Current Liabilities | $264.60M | $357.60M |
| Long-Term Debt | $1.37B | $30.40M |
| Total Shareholders Equity | $234.60M | $1.27B |
| Retained Earnings | $592.50M | $1.06B |
| Property, Plant & Equipment | $45.90M | $321.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NGVT | IOSP |
|---|---|---|
| Operating Cash Flow | $32.70M | $21.70M |
| Capital Expenditures | N/A | $100,000 |
| Free Cash Flow | $15.40M | $12.70M |
| Debt Repayment | $-100.30M | N/A |
| Common Stock Repurchase | N/A | $-4.80M |
Short Interest & Institutional Ownership Analysis
| Metric | NGVT | IOSP |
|---|---|---|
| Shares Short | 1.21M | 260,930 |
| Short Ratio | 5.78 | 1.09 |
| Short % of Float | 0.05% | 0.01% |
| Average Daily Volume (10 Day) | 338,467 | 234,810 |
| Average Daily Volume (90 Day) | 253,409 | 227,103 |
| Shares Outstanding | 36.35M | 24.96M |
| Float Shares | 36.22M | 24.63M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.03% | 1.00% |
Dividend Analysis & Yield Comparison: Ingevity vs Innospec
| Metric | NGVT | IOSP |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.63 |
| Last 12-Month Dividend Yield | N/A | 1.97% |
| 3-Year Avg Annual Dividend | N/A | $1.48 |
| 3-Year Avg Dividend Yield | N/A | 0.70% |
| 3-Year Total Dividends | N/A | $4.45 |
| Ex-Dividend Date | N/A | May 20, 2025 |